Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accu-Chek

- PMLiVE

Making the right mobile health choices

Creative thinking is one of the requirements to ensure lasting healthcare change

- PMLiVE

Apple launches new research software programme

Tech firm made the announcement during the promotion of its new smart watch

UK flag

NHS staff blame cost-cutting for poor diabetes outcomes

Lack of local and national leadership also cited in new ABPI report

FDA launches drug shortages mobile app

USregulator offers the public and HCPs Android and iPhone versions of the app

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

Sanofi reception

Sanofi’s Lantus follow-up nears European approval

CHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

Sanofi joins WHO-backed diabetes mHealth programme

Becomessole pharma partner for Be Healthy, Be Mobile's diabetes arm

Sanofi reception

Sanofi gets green light for Lantus follow-up Toujeo

Once-daily basal insulin gains FDA approval for diabetes

Eli Lilly HQ

Lilly delays filing of Lantus rival on safety concerns

Concerns over changes in liver fat detected in phase III trials

- PMLiVE

Novo Nordisk’s oral GLP-1 analogue looks set for phase III

Semaglutide said to be one of the firm’s most promising prospects

- PMLiVE

Roche’s Zelboraf combination to receive priority FDA review

US regulator to assess drug's use with cobimetinib for melanoma within six months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links